FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a method for the treatment of a subject that is a human with cancer, including a stage of injection of an anti-CD25 antibody to the subject and use of the anti-CD25 antibody for the treatment of solid tumor in the subject, while the specified anti-CD25 antibody is a human IgG1 antibody that binds with high affinity to at least one activating receptor Fcγ selected from FcγRI, FcγRIIc and FcγRIIIa and eliminates regulatory T-cells infiltrating tumor. In one of embodiments, the anti-CD25 antibody has a dissociation constant (Kd) for CD25 of less than 10-8 M and/or a dissociation constant for at least one activating receptor Fcγ of less than approximately 10-6 M.
EFFECT: invention expands the arsenal of means for the treatment of solid tumor in a subject using anti-CD25 antibodies.
17 cl, 17 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2730984C1 |
| COMBINATION OF POXVIRUS ENCODING HUMAN PAPILLOMA VIRUS POLYPEPTIDES, AND IL-2 WITH ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824962C1 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| IMMUNE RESPONSE PRESERVATION DURING CHEMOTHERAPEUTICAL SHEMES | 2017 |
|
RU2779478C2 |
| METHODS FOR INCREASING EFFECTIVENESS OF ANTITUMOUR IMMUNE RESPONSE | 2015 |
|
RU2689162C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| ANTIBODIES TO ICOS | 2016 |
|
RU2742241C2 |
| METHODS FOR IDENTIFICATION, SELECTION, ENRICHMENT AND DEPLETION OF Tr1 CELLS POPULATIONS, Tr1 CELLS POPULATIONS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR THERAPY EFFECT MONITORING | 2011 |
|
RU2627445C2 |
